Drugs / Targeted Activated Dendritic Cells
last change Dec 2025 re-read 3 minutes ago

Targeted Activated Dendritic Cells

Cell therapy

Developed for
high grade malignant neoplasm
Investigated by
Frontiergate Biopharm(Hainan) Co., LTD · Hainan Cancer Hospital

Trials 1

20262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT07475182 Dec 2025 → Dec 2027 expected high grade malignant neoplasm Hainan Cancer Hospital Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Targeted Activated Dendritic Cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT07475182 ↗
Action Activate “activates dendritic cells (DCs)” NCT07475182 ↗
Modality Cell therapy “Autologous dendritic cells (DCs) genetically modified to express chimeric antigen receptor (CAR) and activation domain” NCT07475182 ↗